G-NiiB Oral Microbiome Immunity Formula SIM01 Alleviates Post-COVID-19 Conditions
Clinical Study Published in the Prestigious International Medical Journal The Lancet Infectious Diseases
HONG KONG SAR - Media OutReach Newswire - 8 December 2023 - Hong Kong's leading biomedical and microbiome technology company, G-NiiB GenieBiome, is pleased to announce that a ground-breaking large-scale randomised, double-blind, placebo-controlled clinical trial ("the Trial") conducted on the efficacy of SIM01, an oral microbiome immunity formula developed by a top-notch medical school in Hong Kong, involving 463 patients who had contracted COVID-19, has strongly proved that the consumption of SIM01, an oral microencapsulated live bacteria formula, could significantly improve the gut microbiota after six months and lead to remarkable alleviation of post-COVID-19 sequelae ("long COVID"), encompassing a range of symptoms affecting different systems and organs.Read more: G-NiiB Oral Microbiome Immunity Formula SIM01 Alleviates Post-COVID-19 Conditions
